LLY

754.57

-0.24%↓

JNJ

178.08

-0.17%↓

ABBV

218.3

-0.8%↓

UNH

352.9

-0.29%↓

AZN

79.54

-1.96%↓

LLY

754.57

-0.24%↓

JNJ

178.08

-0.17%↓

ABBV

218.3

-0.8%↓

UNH

352.9

-0.29%↓

AZN

79.54

-1.96%↓

LLY

754.57

-0.24%↓

JNJ

178.08

-0.17%↓

ABBV

218.3

-0.8%↓

UNH

352.9

-0.29%↓

AZN

79.54

-1.96%↓

LLY

754.57

-0.24%↓

JNJ

178.08

-0.17%↓

ABBV

218.3

-0.8%↓

UNH

352.9

-0.29%↓

AZN

79.54

-1.96%↓

LLY

754.57

-0.24%↓

JNJ

178.08

-0.17%↓

ABBV

218.3

-0.8%↓

UNH

352.9

-0.29%↓

AZN

79.54

-1.96%↓

Home・Aktien・Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc

Geschlossen

BrancheGesundheitswesen

36.22 -2.45

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

36.14

Max

36.53

Schlüsselkennzahlen
By Trading Economics
Einkommen	-20M -85M
Gewinnspanne	-867.293
Angestellte	316
EBITDA	-21M -94M

Empfehlungen
By TipRanks
Empfehlungen	Starkes Kaufsignal
12-Monats-Prognose	+47.28% upside

Dividenden
By Dow Jones
Nächstes Ergebnis	11. Nov. 2025

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	327M 2.9B
Vorheriger Eröffnungskurs	38.67
Vorheriger Schlusskurs	36.22

Nachrichtenstimmung

By Acuity

50%

175 / 371 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Strong Bearish Evidence

34.81 / 38.24 Unterstützung & Widerstand

Xenon Pharmaceuticals Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

12. Sept. 2025, 22:41 UTC

Wichtige Markttreiber

GlucoTrack Stock Falls on Plans to Sell $3 Million Note

12. Sept. 2025, 16:04 UTC

Wichtige Markttreiber

Upexi Shares Climb on Solana Gains

12. Sept. 2025, 15:03 UTC

Wichtige Markttreiber

Allied Gaming & Entertainment Shares Surge Following Crypto Investments

12. Sept. 2025, 20:50 UTC

Market Talk

Ergebnisse

Tech, Media & Telecom Roundup: Market Talk

12. Sept. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

12. Sept. 2025, 20:09 UTC

Ergebnisse

Correction to Opendoor Is Sliding. Don't Call It a Meme Stock, Says New Chairman. -- Barrons.com

12. Sept. 2025, 19:23 UTC

Market Talk

Oil Futures End Volatile Week With Moderate Gains -- Market Talk

12. Sept. 2025, 19:16 UTC

Market Talk

Oil Futures End Volatile Week With Moderate Gains -- Market Talk

12. Sept. 2025, 19:03 UTC

Market Talk

Natural Gas Futures Held Back By Plump Inventories -- Market Talk

12. Sept. 2025, 18:59 UTC

Market Talk

Dollar Pares Gains as Economy Keeps Showing Signs of Cooling -- Market Talk

12. Sept. 2025, 18:38 UTC

Market Talk

Ergebnisse

Adobe Seen Reaching Turning Point in AI Cycle -- Market Talk

12. Sept. 2025, 18:33 UTC

Market Talk

U.S. Oil Rig Count Rises By 2 to 416 -- Market Talk

12. Sept. 2025, 18:22 UTC

Market Talk

Canada's Divergence With US On Capex Spending is 'Appalling' -- Market Talk

12. Sept. 2025, 16:56 UTC

Market Talk

Renewable Fuels Association Calls for Nationwide E15 Following WASDE -- Market Talk

12. Sept. 2025, 16:22 UTC

Ergebnisse

Adobe Earnings Were 'Solid.' Long-Term Growth Concerns Remain. -- Barrons.com

12. Sept. 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

12. Sept. 2025, 16:19 UTC

Akquisitionen, Fusionen, Übernahmen

These Stocks Are Moving the Most Today: Warner Bros., Paramount Skydance, Tesla, Super Micro, Microsoft, Figure Technology, and More -- Barrons.com

12. Sept. 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

12. Sept. 2025, 16:11 UTC

Ergebnisse

Novartis Catches a 'Sell.' Goldman Sachs Says the Stock Is Overvalued. -- Barrons.com

12. Sept. 2025, 15:37 UTC

Market Talk

Gold Holds Near All-Time Highs Ahead of Fed Meeting Next Week -- Market Talk

12. Sept. 2025, 15:22 UTC

Market Talk

European Gas Lifted by Geopolitical Risks But Storage Levels Ease Supply Fears -- Market Talk

12. Sept. 2025, 15:07 UTC

Akquisitionen, Fusionen, Übernahmen

These Stocks Are Moving the Most Today: Warner Bros., Paramount Skydance, Tesla, Super Micro, Microsoft, Figure Technology, and More -- Barrons.com

12. Sept. 2025, 14:34 UTC

Market Talk

Russia Sanctions Put Bid Back in Oil -- Market Talk

12. Sept. 2025, 14:10 UTC

Market Talk

Inflation Report Unlikely to Dissuade Canada From Rate Cut -- Market Talk

12. Sept. 2025, 13:58 UTC

Market Talk

Dollar Could Rise if Fed Sounds Cautious on Rate Cuts -- Market Talk

12. Sept. 2025, 13:58 UTC

Akquisitionen, Fusionen, Übernahmen

These Stocks Are Moving the Most Today: Warner Bros., Paramount Skydance, Super Micro, Adobe, Microsoft, Figure Technology, and More -- Barrons.com

12. Sept. 2025, 13:57 UTC

Ergebnisse

AbbVie Stock Hit a Record on 'Big Win' for Blockbuster Drug. The Case for Buying In. -- Barrons.com

12. Sept. 2025, 13:56 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

12. Sept. 2025, 13:56 UTC

Market Talk

Canadian Dollar Faces Further Weakness Vs Non-U.S. Dollar Currencies -- Market Talk

12. Sept. 2025, 13:54 UTC

Market Talk

U.S. Natural Gas Recovers Ground -- Market Talk

Peer-Vergleich

Kursveränderung

Xenon Pharmaceuticals Inc Prognose

Kursziel

By TipRanks

47.28% Vorteil

12-Monats-Prognose

Durchschnitt 53.33 USD 47.28%

Hoch 60 USD

Tief 48 USD

Basierend auf 11 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Xenon Pharmaceuticals Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

11 ratings

Buy

Halten

Sell

Basierend auf 11 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Xenon Pharmaceuticals Inc – Dist abgegeben haben.

Technischer Score

By Trading Central

34.81 / 38.24Unterstützung & Widerstand

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

Stimmung

By Acuity

175 / 371 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.